Founded under its current name in 2000 and headquartered in Irvine, California, Edwards Lifesciences Corp. (EW) is a medical device company that provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company distributes its products through direct sales force and independent distributors.
Edwards Lifesciences Corp. (EW) versus the S&P 500 (YTD)
Six Top Investment Strategies Betting on Edwards Lifesciences Corp. (EW)
- Momentum Factor
The stock is one of the top 120 large- and mid-cap U.S. stocks exhibiting relatively higher price momentum, as measured by a specific factor which has historically driven a significant part of companies’ risk and return.
- Large-Cap Growth
The stock is among the top 50 large-capitalization U.S. growth stocks generated through a rigorous 10-factor fundamental screening process.
- IBD Top Fifty
It is a Top 50 stock based on Investor’s Business Daily’s proprietary trading formula to identify 50 stocks that meet one of seven different catalysts. The “CAN SLIM” strategy identifies companies with either fundamental (improving earnings, new product) or technical (upward stock move on strong volume) catalysts.
- High Quality Stock
The stock exhibits positive fundamentals, including high return on equity, stable year-over-year earnings growth and low financial leverage.
- Insider and Analyst Sentiment
It is one of 100 top stocks out of 5,000 U.S. stocks where a corporate insider (a director or senior officer of a company, or any person or entity that owns more than 10% of the company’s stock) is buying the stock and Wall Street analysts recently have increased earnings estimates.
- Large-Cap Growth and Value
Using a proprietary ranking based on separate models for growth and value, this is a large-cap stock that is part of an index that has historically outperformed its market-cap-weighted benchmark.
Buy Edwards Lifesciences Corp. (EW) at market today, and place your stop at $104.50.
I am holding off on recommending options on this position until the next market pullback.
You were stopped out of your position in Johnson & Johnson (JNJ) last week for a 10.7% gain.
Your position in CDK Global, Inc. (CDK) has dropped below the minimum of five Alpha Algorithm strategies in which it must be included in order to remain in the portfolio. Therefore, I am recommending that you close your position today for a 5.68% gain.
Nicholas A. Vardy